Artelo Biosciences to Present at the H.C. Wainwright 24th Annual Global Investment Conference
September 07 2022 - 8:30AM
Artelo Biosciences,
Inc.
(Nasdaq: ARTL), a
clinical-stage pharmaceutical company focused on modulating
lipid-signaling pathways to develop treatments for people living
with cancer, pain, and neurological conditions, today announced
that Gregory D. Gorgas, Chief Executive Officer of Artelo, will be
presenting at the H.C. Wainwright 24th Annual Global Investment
Conference which is being held September 12 - 14, 2022. The event
will include virtual participation as well as in-person
participation at the Lotte New York Palace Hotel in New York City.
Artelo’s presentation will be available
on-demand to registered attendees via the conference platform
beginning Monday, September 12, 2022, at 7:00 AM Eastern Time.
Management will also be participating in one-on-one meetings with
qualified members of the investment community throughout the
conference.
The webcast of the Company’s presentation at the
conference can also be accessed here and on the investor
relations section of Artelo's website
at https://ir.artelobio.com/ as of 7:00 AM Eastern Time
on Thursday, September 15, 2022.
About Artelo BiosciencesArtelo Biosciences,
Inc. is a clinical-stage pharmaceutical company focused on
modulating lipid-signaling pathways to develop treatments for
people living with cancer, pain, and neurological conditions.
Artelo is advancing a portfolio of broadly applicable product
candidates designed to address significant unmet needs in multiple
diseases and conditions, including anorexia, cancer, PTSD, pain,
and inflammation. Led by proven pharmaceutical executives
collaborating with highly respected researchers and technology
experts, Artelo applies leading edge scientific, regulatory, and
commercial discipline to develop high-impact therapies. More
information is available at www.artelobio.com and
Twitter: @ArteloBio.
Forward Looking Statements
This press release contains certain
forward-looking statements within the meaning of Section 27A of the
Securities Act of 1933 and Section 21E of the Securities Exchange
Act of 1934 and Private Securities Litigation Reform Act, as
amended, including those relating to Artelo’s product development,
clinical and regulatory timelines, market opportunity, competitive
position, possible or assumed future results of operations,
business strategies, potential growth opportunities and other
statement that are predictive in nature. These forward-looking
statements are based on current expectations, estimates, forecasts
and projections about the industry and markets in which we operate
and management’s current beliefs and assumptions. These statements
may be identified by the use of forward-looking expressions,
including, but not limited to, “expect,” “anticipate,” “intend,”
“plan,” “believe,” “estimate,” “potential,” “predict,” “project,”
“should,” “would” and similar expressions and the negatives of
those terms. These statements relate to future events or our
financial performance and involve known and unknown risks,
uncertainties, and other factors which may cause actual results,
performance or achievements to be materially different from any
future results, performance or achievements expressed or implied by
the forward-looking statements. Such factors include those set
forth in Artelo’s filings with the Securities and Exchange
Commission, including our ability to raise additional capital in
the future. Prospective investors are cautioned not to place undue
reliance on such forward-looking statements, which speak only as of
the date of this press release. Artelo undertakes no obligation to
publicly update any forward-looking statement, whether as a result
of new information, future events or otherwise, except to the
extent required by applicable securities laws.
Investor Relations Contact:Crescendo
Communications, LLCTel:
212-671-1020Email: ARTL@crescendo-ir.com
Artelo Biosciences (NASDAQ:ARTL)
Historical Stock Chart
From Aug 2024 to Sep 2024
Artelo Biosciences (NASDAQ:ARTL)
Historical Stock Chart
From Sep 2023 to Sep 2024